Latest Regulatory Developments News

Vectus Biosystems has secured a pre-IND Type B meeting with the FDA for its lead IPF drug candidate VB0004. The regulator’s written feedback, expected by mid-November, should clarify the next US development steps but does not yet authorise clinical trials.

Enova Mining has launched a 1-for-4 entitlement offer at A$0.001 a share to raise up to A$495,152 for exploration and working capital. The modest raising sits alongside a proposed A$2 million placement and potential Caraubas acquisition issues that could materially expand the share count.

Actinogen Medical has completed the final patient visit in its 247-participant XanaMIA Alzheimer’s disease trial, keeping topline results on track for November 2026. The milestone closes patient participation in the pivotal study, but provides no indication yet of whether Xanamem improved outcomes.

Peak Processing Limited’s FY26 results reveal a doubling loss from continuing operations to $10 million amid a $4.35 million impairment, offset partially by a $2.5 million profit from discontinued operations. The company completed an operational reset and posted its first positive EBITDA quarter in June 2026.

PEXA Group delivered a solid FY26 with 7% revenue growth and a return to profitability, while facing a regulatory pricing review that could reshape its future investment capacity.

Bisalloy Steel’s FY26 profit fell 16% as softer domestic demand and Indonesian import restrictions weighed, but the company secured a pioneering US submarine steel order and advanced its digital wear-monitoring technology.

Chorus reported solid FY26 results with revenue growth driven by fibre expansion and disciplined cost management, while accelerating copper network retirement and launching new digital infrastructure services.

Lifestyle Communities reported a transformative FY26 with a sharp rebound in new home sales, substantial debt reduction, and record homeowner satisfaction, despite ongoing market headwinds and regulatory uncertainty.

APA Group (ASX:APA) posted an 81% jump in net profit after tax to AUD 234 million for FY26, driven by strong EBITDA growth, cost savings, and contributions from new assets. The company declared its 22nd consecutive distribution increase, advancing key infrastructure projects and sustainability goals.

Australian Finance Group (ASX:AFG) reported a 39% jump in FY26 net profit after tax to AUD 48.5 million, driven by growth across its broker network and lending book, alongside its first mandatory climate disclosures.

Medibank Private Limited reported a 27.5% jump in net profit after tax to $638.7 million for FY26, driven by steady health insurance growth and a 31.3% surge in its Medibank Health segment. The company declared a fully franked final dividend of 10.9 cents per share and updated its Net Zero emissions strategy.

SCX.ai Holdings Limited is set to raise $40 million through a fully underwritten IPO at $0.30 per share, aiming to scale its sovereign AI inferencing platform built on ASIC hardware within Australian data centres. The company targets the fast-growing AI IaaS market with a focus on secure, low-latency AI workloads.